DelveInsight's "FABHALTA Market Size, Forecast, and Market Insight Report" highlights the details around FABHALTA, an oral complement factor B inhibitor used to treat adults with paroxysmal nocturnal ...

With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...